Jim McCamant, Editor at Large

Jim McCamant has been in the investment business for 40 years.  He served as Editor of the Medical Technology Stock Letter from its inception in December 1983 through August 2000.  The Medical Technology Stock Letter was the best performing investment advisory letter in 1995, as measured by the Hulbert Financial Digest.  Mr. McCamant is widely quoted in the business press as an expert on investing in biotechnology stocks.  He is a graduate of Stanford University and served three years in the United States Marine Corps.  He has focused on growth stocks during his investment career and was one of the first analysts to follow the electronics industry on the West Coast.  He has followed the biotechnology sector since Genentech's initial public offering in the fall of 1980.

Book Offer

From the editor of the most influential biotech newsletter comes the most comprehensive investment guide on biotechnology.  Biotechnology is indisputably one of the fastest-growing and most promising industries.  Virtually immune to swings in the economic cycles, biotech stocks continue to perform steadily as high-tech stocks lose their steam.  In Biotech Investing, Jim McCamant offers proven strategies and savvy advice on how to capitalize on the unprecedented opportunities in this high-potential sector.  Written by a recognized authority, this book dissects biotech business models from start-up to IPO and discusses in detail the most important factors that affect biotech research.  Comprehensive in scope, it looks at the best and worst biotech contenders, discusses all the most newsworthy developments in the field, and shows how they translate into business success or failure.  It outlines simple criteria for choosing the best biotech  stocks and for understanding the sometimes complicated dynamics of this sector.